Market
Gilead Sciences stock price change post-FDA approval of Trodelvy for NSCLC by end of 2025
2
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change or decrease • 25%
Stock market data providers (e.g., Bloomberg, Yahoo Finance)
Story
FDA Grants Breakthrough Therapy Designation to Trodelvy for Advanced NSCLC and Extensive-Stage Small Cell Lung Cancer
Dec 17, 2024, 01:36 PM
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to sacituzumab tirumotecan, also known as Trodelvy, for the treatment of advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutations that have progressed after treatment with a tyrosine kinase inhibitor (TKI) and chemotherapy. This designation is significant for Gilead Sciences, as it enhances the potential for expedited development and review of the therapy. Additionally, the FDA has also recognized Trodelvy for use as a second-line treatment for extensive-stage small cell lung cancer, marking another important milestone for the drug's application in oncology.
View original story
Similar markets
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
Accelerated Approval • 25%
Moderate Improvement • 25%
Significant Improvement • 25%
No Change • 25%
Worse Outcomes • 25%
Leading • 25%
Third • 25%
Lower • 25%
Second • 25%
No • 50%
Yes • 50%
No change • 25%
Decrease • 25%
Increase by 10% or more • 25%
Increase by less than 10% • 25%
Decrease by more than 20% • 25%
Increase by more than 20% • 25%
Increase by 0-20% • 25%
Decrease by 0-20% • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
No significant change • 25%
Decrease • 25%
Underperforms the biotech index • 25%
Performs in line with the biotech index • 25%
Highly volatile with no clear trend • 25%
Outperforms the biotech index • 25%